The sustained increase of cardiovascular risk following COPD exacerbations: meta-analyses of the EXACOS-CV studies
Open Access
- 27 November 2024
- journal article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (3)
Abstract
Background: The EXAcerbations of COPD and their OutcomeS on CardioVascular disease (EXACOS-CV) multi-database studies have consistently shown an increased risk of serious cardiovascular event following COPD exacerbations, but with some risk temporality variations. EXACOS-CV results were meta-analysed to increase their generalisability and improve precision.Methods: Studies conducted in Canada, the United States, Germany, the Netherlands, Spain, Italy, Japan and England were meta-analysed, amounting to 1 030 875 individuals. Generally, each study included individuals aged ≥40 years with a COPD diagnosis in 2014–2019; primary outcome was the composite of non-fatal acute coronary syndrome, decompensated heart failure, ischaemic stroke, arrhythmias and all-cause death. Pooled hazard ratios (HRp) of risks in post-exacerbation periods (versusperiods outside exacerbations) were obtained through random effects meta-analysis.Results: Time periods following an exacerbation (any severity) were associated with increased and sustained risks of the composite outcome: HRp10.22 (95% CI 5.34–19.57) in days 1–7 and HRp1.24 (95% CI 1.09–1.40) in days 181–365. Risks were elevated for 6 months (HRp1.25, 95% CI 1.01–1.55 in days 31–180) and 1 year (HRp1.48, 95% CI 1.11–1.96 in days 181–365) following a moderate or a severe exacerbation, respectively. In newly diagnosed individuals, risks were increased until days 31–180: HRp1.66 (95% CI 1.14–2.42) and HRp1.61 (95% CI 1.28–2.02) following the first and the second post-diagnosis exacerbation, respectively.Conclusion: Risk of severe cardiovascular events is sustainably increased following an exacerbation of COPD, even early and moderate ones. Cardiopulmonary risk reduction should be a global core target of COPD management.Keywords
Funding Information
- AstraZeneca
This publication has 32 references indexed in Scilit:
- Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPDRespirology, 2019
- Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPDJournal of General Internal Medicine, 2018
- Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisThe Lancet Respiratory Medicine, 2015
- Cardiovascular Comorbidity in COPDChest, 2013
- Confidence intervals for the between‐study variance in random effects meta‐analysis using generalised Cochran heterogeneity statisticsResearch Synthesis Methods, 2013
- Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPDChest, 2010
- Undue reliance on I 2 in assessing heterogeneity may misleadBMC Medical Research Methodology, 2008
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986